Moore Capital Management LP Buys 25,000 Shares of CVS Health Corporation $CVS

Moore Capital Management LP grew its stake in CVS Health Corporation (NYSE:CVS) by 7.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 350,000 shares of the pharmacy operator’s stock after acquiring an additional 25,000 shares during the period. Moore Capital Management LP’s holdings in CVS Health were worth $27,776,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in CVS. Alteri Wealth LLC lifted its position in shares of CVS Health by 3.2% in the 3rd quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock worth $316,000 after purchasing an additional 131 shares during the period. TOWER TRUST & INVESTMENT Co lifted its position in CVS Health by 0.8% during the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock valued at $1,247,000 after acquiring an additional 132 shares during the last quarter. CYBER HORNET ETFs LLC lifted its position in CVS Health by 4.1% during the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after acquiring an additional 134 shares during the last quarter. LS Investment Advisors LLC raised its holdings in shares of CVS Health by 3.9% in the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after buying an additional 135 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its holdings in shares of CVS Health by 4.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock worth $239,000 after buying an additional 135 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. Company insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a report on Thursday, June 11th. Argus increased their price objective on shares of CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Wells Fargo & Company increased their price objective on shares of CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, DA Davidson increased their price objective on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Twenty-two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.68.

CVS Health Stock Down 1.6%

CVS stock opened at $99.06 on Thursday. The firm has a market cap of $126.40 billion, a PE ratio of 43.64, a P/E/G ratio of 0.99 and a beta of 0.62. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm’s fifty day moving average is $88.51 and its 200 day moving average is $81.24. CVS Health Corporation has a one year low of $58.50 and a one year high of $102.77.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the business earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts forecast that CVS Health Corporation will post 7.44 EPS for the current year.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.